Stock Market News
Hikma appoints Surendera Tyagi as chief scientific officer
Hikma Pharmaceuticals has appointed Surendera Tyagi as group chief scientific officer and global head of research and development.
Tyagi will focus on the company's non-injectables business during the first year and will become a member of the Executive Committee.
Chairman and chief executive Said Darwazah said: "Surendera is an outstanding scientist with a proven track record of leading research and development in some of the world's largest and most successful pharmaceutical organisations.
"Research and innovation is one of our five pillars for growth and the appointment of Surendera is a significant step forward in executing on this strategy. We are very excited for Surendera to be joining us and accelerating our ability to develop novel ways to improve the health of people around the world."
Tyagi joins Hikma from Fresenius Kabi, where he most recently led the US Innovation & Development Center. He also successfully expanded the company's oncology business. Prior to joining Fresenius, Tyagi served as chief scientific officer for Dabur Pharma, an oncology company that was acquired by Fresenius in 2008. He also has held scientific and/or regulatory roles at Roche, IGEN, Abbott/Hospira, and Schwarz Pharma.
Tyagi said: "Hikma's track record of delivering affordable, quality medicines to people who need them is a purpose that I share. I look forward to accelerating their R&D efforts by advancing and expanding their pipeline, leveraging Hikma's highly experienced and talented R&D team."
Tyagi will focus on the company's non-injectables business during the first year and will become a member of the Executive Committee.
Chairman and chief executive Said Darwazah said: "Surendera is an outstanding scientist with a proven track record of leading research and development in some of the world's largest and most successful pharmaceutical organisations.
"Research and innovation is one of our five pillars for growth and the appointment of Surendera is a significant step forward in executing on this strategy. We are very excited for Surendera to be joining us and accelerating our ability to develop novel ways to improve the health of people around the world."
Tyagi joins Hikma from Fresenius Kabi, where he most recently led the US Innovation & Development Center. He also successfully expanded the company's oncology business. Prior to joining Fresenius, Tyagi served as chief scientific officer for Dabur Pharma, an oncology company that was acquired by Fresenius in 2008. He also has held scientific and/or regulatory roles at Roche, IGEN, Abbott/Hospira, and Schwarz Pharma.
Tyagi said: "Hikma's track record of delivering affordable, quality medicines to people who need them is a purpose that I share. I look forward to accelerating their R&D efforts by advancing and expanding their pipeline, leveraging Hikma's highly experienced and talented R&D team."
Related share prices |
---|
Hikma Pharmaceuticals (HIK) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price